Drug intelligence / Profile preview

rAAV9-GFP

Development stage
Preclinical
Lead developer
UT Southwestern Medical Center
Modality
Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration
Intravenous, Intrathecal, Intracerebral, Intramuscular
01

Overview

rAAV9-GFP is a research-grade recombinant adeno-associated virus serotype 9 (rAAV9) vector that encodes green fluorescent protein (GFP), typically driven by a constitutive promoter such as CMV (cytomegalovirus). It is a widely utilized gene therapy research tool used to study vector distribution, transduction efficiency, and cellular tropism in various tissues, including the brain, spinal cord, kidney, and liver. In preclinical studies, rAAV9-GFP serves as a reporter construct, allowing researchers to visualize successfully transduced cells via fluorescence microscopy. It is frequently employed as a control or pilot vector in animal models (such as mice, rats, and non-human primates) to optimize delivery strategies for therapeutic gene candidates. This tool is produced by various research suppliers and is not associated with a specific pharmaceutical company as a commercial drug candidate.

Other names
AAV9-CMV-GFPAAV-9-CMV-GFPAAV 9-CMV-GFPrecombinant adeno-associated virus serotype 9-green fluorescent protein
02

Targets

ASGPR (Asialoglycoprotein Receptor 1)RPSA (37/67 kDa laminin receptor)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))

Beyond the preview

Go deeper on rAAV9-GFP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rAAV9-GFP.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call